Intracorporeal Vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy
Randomized Clinical Trial of Intracorporeal Vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shashana Fiedler
- Phone Number: 305-243-6438
- Email: sxf780@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Biopsy-proven urothelial cancer being considered for RARC.
- Clinical stage T1-T4, N0-1, M0 or refractory carcinoma in situ.
- Subject must be already scheduled to have a RARC at the discretion of the surgeon and with the patient's agreement.
Exclusion Criteria:
- Inability to give informed consent
- Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.
- At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.
- Age <18 or >99 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Extracorporeal Urinary Diversion (ECD)
Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
|
Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
Other Names:
|
|
Experimental: Intracorporal Urinary Diversion (ICD)
Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
|
Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90-day Major Post-Operative Complication Rate
Time Frame: 90 days
|
Major complication rate at 90-days from RARC + urinary diversion using the modified Clavien-Dindo grading system.
Major complication is defined as Clavien-Dindo Grade ≥ 3.
|
90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90-day Any Post-Operative Complication Rate
Time Frame: 90 days
|
Any complication rates at 90-days from RARC + urinary diversion, using the modified Clavien-Dindo grading system as low grade (1-2) or high grade (3-5).
|
90 days
|
|
Length of Hospital Stay in ECD vs ICD Study Participants
Time Frame: About 2 weeks
|
Length of hospital stay for study participants undergoing ECD versus ICD urinary diversion post-RARC, as recorded at hospital discharge.
|
About 2 weeks
|
|
90-day Readmission Rate
Time Frame: 90 days
|
Rate of readmission to hospital at 90 days post-RARC followed by ECD or ICD urinary diversion.
|
90 days
|
|
Rate of Return to the Operating room within 90 days
Time Frame: Up to 90 days
|
Rate of return to the operating room within 90 days after RARC followed by ICD or ECD Urinary Diversion.
|
Up to 90 days
|
|
Mortality Rate at 90 days
Time Frame: 90 days
|
Rate of mortality (death) at 90 days in study participants
|
90 days
|
|
Rate of Bowel-Specific Complications
Time Frame: Up to 36 months
|
Rate of bowel-specific complications in study participants (including incidence of mechanical bowel obstruction, anastomotic leaks, and surgical site infections) and post operative pain.
Bowel-specific complications will be assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.
|
Up to 36 months
|
|
Functional Independence Recovery as measured by the ADL Questionnaire
Time Frame: Up to 36 months
|
Rate of functional independence recovery as measured by patient-reported scores on the Activities of Daily Living (ADL) questionnaire.
For the ADL, the total score ranges from 0 to 6, with the higher scores indicating functional improvement and lower scores indicating functional deterioration.
|
Up to 36 months
|
|
Functional Independence Recovery as measured by the IADL Questionnaire
Time Frame: Up to 36 months
|
Rate of functional independence recovery as measured by an aggregate of patient-reported scores on the Instrumental Activities of Daily Living (IADL) questionnaire.
For the IADL, the total score ranges from 0 to 8, with higher scores indicating functional functional improvement and lower scores indicating functional deterioration.
|
Up to 36 months
|
|
Functional Independence Recovery as measured by the Hand Grip Strength Test.
Time Frame: Up to 36 months
|
The Hand Grip Strength Test measures the amount of static force that a participant's hand can squeeze around a dynamometer.
The test is measured in kilograms.
|
Up to 36 months
|
|
Functional Independence Recovery as measured by the Timed Up and Go (TUG) Walking Test
Time Frame: Up to 36 months
|
The TUG test times participants as they rise from a standard chair, walk 3 meters, turn, walk back and sit again.
The test is measured in seconds.
|
Up to 36 months
|
|
Health-Related Quality of Life (HRQoL) as assessed by SF-8 Health Survey
Time Frame: Up to 36 months
|
HRQoL measured by patient scores on the Short Form 8 (SF-8) Health Survey.
The SF-8 is a questionnaire consisting of 8-items and two component summary scores: Physical component summary (PCS) and mental component summary (MCS).
They are scored by weighting each score to a norm-based scoring model.
The total scores will be reported as a percentile with higher score indicating better health-related quality of life.
|
Up to 36 months
|
|
HRQoL as assessed by the FACT-VCI Questionnaire
Time Frame: Up to 36 months
|
HRQoL measured by patient scores on the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) questionnaire.
The FACT-VCI is a condition-specific instrument for patients undergoing radical cystectomy (RC) and urinary diversion (UD) for bladder cancer.
The questionnaire consists of 44 items scored on a range from 0 ("Not at all") to 4 ("Very Much"), resulting in an ordinal Likert scale, with higher scores indicating a better HRQoL.
The FACT-VCI measures quality of life across five domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and an additional concerns subscale.
|
Up to 36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mark L Gonzalgo, MD, PhD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20170004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.